Fig. 8

TRIM8 is pivotal in controlling chemotherapy cell sensitivity. a Cell proliferation by MTT reduction assay in RCC-Shaw transfected with Negative Control miRNA Mimic or anti-miR-17-5p plus control short hairpin-RNA (control shRNA) or specific short hairpin against TRIM8 (shRNA-TRIM8) (** p-value < 0.005). After transfection the cells were treated with Nutlin-3 (N) (10 μM), Cisplatin (C) (7.5 μM), Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or drug-untreated cells(-). For each cell line, drug-untreated sample transfected with control miRNA has been used as calibrator (fold 1.0). Cells transfected with anti-miR-17-5p plus control shRNA or shRNA-TRIM8, or with control miRNA and treated with the different drugs have been normalized with respect to this calibrator. b Western blotting analysis of the indicated proteins in RCC-Shaw transfected with Negative Control miRNA Mimic or anti-miR-17-5p plus control short hairpin-RNA or specific short hairpin against TRIM8 (shRNA-TRIM8). After transfection the cells were treated with Nutlin-3 (N) (10 μM), Cisplatin (C) (7.5 μM), Sorafenib (S) (10 μM), Axitinib (A) (10 μM) or drug-untreated cells (-). Western blot of Actin was conducted as control